Rob. you, Thank
can we've strategic Rob X nutraceutical months been March pioneering continue we this to improve that LLC a executing strategic aspects and of XX, on financial doing shift devoted I'd to into company progress. the driven than last The and Frank acquisition people shift that XXXX; to to technologies shift, the like way months place of better took As stock the the XX for a on be [ph]. expected. you date has Healthspan marks update noted, Research consumer our our
fourth brands First, result related Despite quarter Watsons. and partner, said, and having of as the the This a by in in of throughout the NIAGEN our from TRU NIAGEN XXXX of to agreeing away marketplace. year fewer NIAGEN. our shift we retail increased growth the full driven Rob resellers sales number is and reduced a significantly truniagen.com revenues in customers,
began Second, brand we in TRU with our successful in launch partner quarter our international Kong third Singapore. quarter in with the the followed of a Watsons of by XXXX the and NIAGEN first expansion Macau Hong launch
the Now financial let's quarter look our results XXXX. fourth at of for
reported XX, of up ended the from quarter NIAGEN. in $X.X the growth months December XX% three XXXX the For by of sales fourth million, fourth ChromaDex driven to operations of compared TRU of net in XXXX. quarter million was the sales continued $X.X increase The
the of was sales. revenues which For quarter, related quarter represented $X.X fourth NIAGEN fourth million XX%
margins We also delivered XX.X% compared XXXX. TRU for up the for XXX delivered to sales. to quarter XX.X% better by profits was the mix approximately quarter as basis of fourth points NIAGEN gross fourth the of positive of We gross due improved which
These $X.X company in for million expenses million increase quarter $X.X in business. in compared of million fourth $X.XX an million administrative expenses by expenses $X.X investments marketing of fourth $X.X in as approximately the and marketing for to to which the of severance $X.X Sales by expense The million the $X.X the accelerate invest as last million we from attributable fourth million to $X.X The in quarter general $X.X human higher we $X.X balance of to and to clinical million fourth the to million quarter building to $X.X offset quarter, related in General quarter driven million growth litigations equity expenditures, million in were higher to people $X.X support future our to brand. stockholders and investments our million Company research increased IT of compared as by million. marketing to legal $X.X and increased sales trials was and was out as expenses development. continue related quarter $XX.X investments The The development million made up capabilities, fourth bad lower for debt by infrastructure growth. $X.X of to and and new and NR the and common net million $X.X last to development, Our to investment increase XXXX. million, the and related up incremental XXXX loss operating year. compared technology expense. was build TRU compensation expenses incurred by of as NIAGEN make fees expenses research year and administrative continue
million expect we to growth of share quarter based forward, global negative XXXX a during compared is share, TRU million negative adjusted the compensation operations continue in non-GAAP per which adjusted $X.X a negative XXXX of was capture Looking $X.X to prior invest fourth EBITDA $X.XX last the ahead year. NIAGEN. a measure quarter to $X.XX share from per for Loss year. for EBITDA was negative non-cash a to associated the share opportunity the per of of charges to fourth for with continuing compared
XXXX fourth solid We $XX.X also ended the quarter sheet year-end a cash balance million. with with of of
decrease company full X% to an net December year reported million was as to of XX, from $XX.X year compared This testing for operations, from global to company. due for a year consumer business of and focused a shift decrease ended Turning XXXX. XXXX; the $XX.X the in nutraceutical sales largely ingredient XXXX ChromaDex million strategy continuing to full
up net million million Net half by increase $XX.X second XX% second an were due NIAGEN. sales of as million, the $X.X the For of to were XXXX. to XXXX, the sales half TRU compared $X.X in of
to million XX.X% in loss million, common up invested points shareholders We also net XXX year $XX.X of profit was basis for we was the up XX% which XXXX NIAGEN. by attributable which improved to for gross $X.X full year TRU for full marketing the buildout compared approximately was XXXX. delivered full by as expenditures to The as year
measure stock-based higher $X.X associated negative year. $X.X share million, share during of of adjusted non-cash a XXXX incurred compared XXXX was we to the million negative full million to year. for EBITDA and share year costs EBITDA compensation with associated a addition, a adjusted $X.XX year negative share-based In the per for non-GAAP was of million. Loss which operations prior legal compared negative is the in a per continuing higher and litigation ongoing compensation with per last the a expense charges from $X.X full $X.XX $X.X
and Company we of look launch to expects in the the international As to by significant business our to in forward growth continue TRU driven deliver XXXX, markets. new sales Watson U.S. e-commerce NIAGEN international and business
are growth XXXX to and grow U.S. half NIAGEN the be the Watson's the of businesses in international expected will new We as back skewed the launched towards of full expected to we and year markets. TRU continue year
and partner discussion that NIAGEN at resellers sales expected or our are Our NIAGEN currently in TRU U.S., Blue NIAGEN sales partners ingredient in sales essentially the four we're through Watsons, prospective through international analyzing new sales for come Chip markets. retail international at TRU sales in with NIAGEN at to from to segments; U.S., the TRU
U.S. and in yet represents capture of to XXXX estimate share million to currently to these in sales Xx ingredient sales we sales $X sales as be expect much in We to about XXXX. which for around continue versus down to slightly we the retail to not in resellers XXXX whine as significant $XX in $X ingredient our approximately forecast our in of million We down NIAGEN expect XXXX. we're to sales million to able be million we see that segments these growth that except this XXXX these resellers to $XX
on of throughout will business that NIAGEN continue buildout the anticipate grow year. we -- NIAGEN, we TRU our TRU As the focus our
Although Hong the as growth. fourth net expected in support to to year-over-year due of absolute to we the the TRU XXXX to new sales invest are sales to growth, of NIAGEN in takeaway quarter sales for quarter, dollars in infrastructure marketing NIAGEN lower Watsons in consumer in despite grow maybe well TRU continued as from to first ingredient ahead build timing the out and capabilities in first and strong Macau. orders Also, NIAGEN continue quarter Kong plan of less
XXXX expect sales. continue to better TRU in to We improve percentage mix our will due revenues gross NIAGEN profit of to
growth marketing, to We we and invest infrastructure move markets to also we new expect key into ahead build in global of as continue capabilities.
TRU more markets. We also NIAGEN is a of science global continue awareness significant growth and NIAGEN to believe launch there increases opportunities in and new beyond that international published tremendous as we TRU for continue to XXXX in to is
than of our year-end I'll more for on fund Finally, open to operator. the is With hand call we and questions cash expect not operations XXXX $XX enough that, million the XXXX at in beyond.